Table 2.

Meta-analysis of case-control studies for NQO1 Pro187Ser polymorphisms and lung, bladder, and colorectal cancer risk

No. studiesOR* for variant genotype (95% CI)Test for heterogeneity PEgger's test P
Lung cancer
    Overall
        CT141.04 (0.92-1.19)0.020.59
        TT141.07 (0.98-1.16)0.030.69
        CT/TT19§0.97 (0.86-1.10)<0.010.79
    White
        CT81.07 (0.98-1.16)0.870.07
        TT81.19 (0.94-1.50)0.440.60
        CT/TT111.04 (0.96-1.13)0.340.81
    Asian
        CT7**1.00 (0.70-1.43)0.010.10
        TT7**0.95 (0.58-1.55)<0.010.81
        CT/TT8††0.99 (0.72-1.34)<0.010.15
    Black
        CT/TT3‡‡0.95 (0.66-1.36)0.630.57
Bladder cancer
    Overall
        CT8§§1.06 (0.90-1.25)0.100.19
        TT8§§1.27 (0.90-1.80)0.260.31
        CT/TT8§§1.09 (0.93-1.28)0.320.38
    White
        CT6∥∥1.19 (0.99-1.44)0.580.04¶¶
        TT6∥∥1.24 (0.81-1.90)0.110.18
        CT/TT6∥∥1.20 (1.00-1.43)0.690.29
Colorectal cancer
    Overall
        CT6***1.15 (1.01-1.32)0.330.82
        TT6***0.93 (0.68-1.26)0.120.72
        CT/TT6***1.13 (0.99-1.28)0.200.84
    White
        CT5†††1.18 (1.03-1.37)0.340.88
        TT5†††1.10 (0.77-1.57)0.240.89
        CT/TT5†††1.18 (1.02-1.35)0.360.77